KDM2B and prostate carcinoma: This study confirmed the increased expression of KDM2B in CTCs from prostate cancer patients revealing that 85% of the patients harbored KDM2B-positive CTCs, which is line with the results from the smaller group of patients, implying that this expression is a common phenomenon for prostate cancer.